Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 9;16(16):2804.
doi: 10.3390/cancers16162804.

The Effects of Gynecological Tumor Irradiation on the Immune System

Jesus Romero Fernandez  1 , Sofia Cordoba Largo  1 , Raquel Benlloch Rodriguez  1 , Beatriz Gil Haro  1
Affiliations
Review

The Effects of Gynecological Tumor Irradiation on the Immune System

Jesus Romero Fernandez et al. Cancers (Basel). .

Abstract

Radiobiology has evolved from a mechanistic model based on DNA damage and response factors into a more complex model that includes effects on the immune system and the tumor microenvironment (TME). Irradiation has an immunomodulatory effect that can manifest as increased anti-tumor immunity or immunosuppression. Irradiation promotes an inflammatory microenvironment through the release of pro-inflammatory cytokines and endothelial damage, which recruit immune system cells to the irradiated area. Radiation-induced immunogenic cell death (ICD), characterized by the release of damage-associated molecular patterns (DAMPs) and tumor antigens, triggers an anti-tumor immune response of both innate and adaptive immunity. Anti-tumor immunity can manifest at a distance from the irradiated area, a phenomenon known as the abscopal effect (AE), which involves dendritic cells and CD8+ T cells. Irradiation also produces an immunosuppressive effect mediated by tumor-associated macrophages (TAMs) and regulatory T lymphocytes (Tregs), which counterbalances the immunostimulatory effect. In this work, we review the mechanisms involved in the radiation-induced immune response, which support the combined treatment of RT and immunotherapy, focusing, where possible, on gynecologic cancer.

Keywords: abscopal effect; gynecological cancer; radiation-induced immune effects; radiobiology; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Therapeutic index: the therapeutic index is established by comparing the sigmoidal dose–response curve for tumor control (red) with that for toxicity (blue). The dashed lines represent the modification of the dose-response curves due to the antitumor immune response (red) or to techniques that spare healthy tissues such as IMRT or brachytherapy (blue).
Figure 2
Figure 2
Linear–quadratic model. α parameter (red) represents a non-repairable lesion produced by a single irradiation event (linear component), and β parameter (blue) represents several repairable lesions produced by independent events (quadratic component).
Figure 3
Figure 3
Schematic representation of the complex network of the immune response pathways triggered by irradiation. DSB: double-strand DNA break; cGAS: cyclic GMP-AMP synthase; STING: stimulator of interferon genes; IFN: interferon; CCL2, CCL19, CCL21, and CCL22: chemokines; TAAs: tumor antigens; ICD: immunogenic cell death; ATP: adenosine triphosphate; CALRT: calreticulin; HMGB1: high-mobility group protein B1; P2X, CD91, and TRL4: pattern recognition receptors; DC: dendritic cell; MHC: major histocompatibility complex; TCR: T-cell receptor; TNFα: tumor necrosis factor-alpha; ROS: reactive oxygen species; IL: interleukin; TGFβ: transforming growth factor-beta; NFκB: nuclear factor kappa B; TAM: tumor-associated macrophage; TAN: tumor-associated neutrophil; Treg: regulatory T lymphocyte.
See this image and copyright information in PMC

References

    1. Baskar R., Lee K.A., Yeo R., Yeoh K.W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012;9:193–199. doi: 10.7150/ijms.3635. - DOI - PMC - PubMed
    1. Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S., Ledermann J., Bosse T., Chargari C., Fagotti A., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021;31:12–39. doi: 10.1136/ijgc-2020-002230. - DOI - PubMed
    1. Cibula D., Raspollini M.R., Planchamp F., Centeno C., Chargari C., Felix A., Fischerová D., Jahnn-Kuch D., Joly F., Kohler C., et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer—Update 2023. Int. J. Gynecol. Cancer. 2023;33:649–666. doi: 10.1136/ijgc-2023-004429. - DOI - PMC - PubMed
    1. Cordoba Largo S., Rodriguez Rodriguez I., Rodriguez Villalba S., Najjari Jamal D., Anchuelo Latorre J., Celada Álvarez F., Garcia Cabezas S., de la Fuente Alonso C., Couselo Paniagua L., GINECOR (Spanish Gynaecological Tumors Group of SEOR) Radiation therapy for vulvar cancer: Consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 1: Clinical recommendations. Clin. Transl. Oncol. 2023;25:2153–2168. doi: 10.1007/s12094-023-03095-8. - DOI - PubMed
    1. Mahantshetty U., Poetter R., Beriwal S., Grover S., Lavanya G., Rai B., Petric P., Tanderup K., Carvalho H., Hegazy N., et al. IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer. Radiother. Oncol. 2021;160:273–284. doi: 10.1016/j.radonc.2021.05.010. - DOI - PMC - PubMed

LinkOut - more resources